We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lexicon Loses Appeal of Complete Response Letter for Diabetes Treatment
Lexicon Loses Appeal of Complete Response Letter for Diabetes Treatment
Lexicon Pharmaceuticals has lost its appeal to the FDA of the agency’s complete response letter in March for its investigational add-on type 1 diabetes treatment Zynquista (sotagliflozin).